^AUSTIN, Texas, Aug. 31, 2023 (GLOBE NEWSWIRE) — XBiotech Inc. today announced the
Announced Completion of Enrollment for the Phase II Portion of its 1-BETTER Trial,
which is a randomized, double-blind, placebo-controlled
Phase I/II clinical trial evaluating Natrunix in combination with
chemotherapy for the treatment of pancreatic cancer.
Natrunix is not derived from a naturally occurring antibody in a healthy person
distinguish people. Natrunix binds and neutralizes a highly effective
A substance called a cytokine known as interleukin-1a (IL-1a).
and the breakdown of connective tissue, the formation of new blood vessels and recruitment
white blood cells caused. Malignant tumors such as pancreatic cancer
stimulate the body’s production of IL-1a, which promotes neovascularization,
promotes the growth and spread of the tumor. In addition, IL-1a acts
as an alarm signal in the event of damage to the body (e.g. when tumors grow),
by affecting pain perception as well as metabolism, appetite, and fatigue
increased anxiety. The stresses of chemotherapy also lead to
Production of IL-1a. Therefore, the use of Natrunix in combination with
Chemotherapy offers numerous advantages, e.g. B. an anti-tumor effect,
less side effects of chemotherapy, greater effectiveness of
Chemotherapy and a higher number of therapy cycles that are tolerated
can, while at the same time improving the quality of life.
22 leading cancer centers in the USA are participating in the phase I/II study.
Pancreatic cancer is the fourth leading cause of cancer-related death in
the USA and the incidence has been steadily increasing since 2000. In 2022 died in the
US estimated 50,000 people from pancreatic cancer. The Natrunix
Antibody therapy represents a groundbreaking therapeutic approach.
In phase II of the study, 65 patients were included who were in phase I of the
study were treated with the maximum dose investigated. The patients
were randomized in a 1:1 ratio to receive either Natrunix in
Combination with ONIVYDE+LV+5-FU (Arm 1) or placebo plus die
chemotherapy combination. The main endpoints in the phase II part of the study
are the efficacy and tolerability, the progression-free survival, the
Overall survival and time to treatment failure.
About Natrunix
Natrunix is a True Human(TM) antibody discovered and developed by XBiotech
developed and manufactured by the company itself. TrueHuman(TM)-
Antibodies are obtained without further modification from individuals who have a
have natural immunity to certain diseases. With many people
The body naturally forms antibodies to pathological ones
Counteract inflammation associated with Interleukin-1
one of the most extensively studied inflammatory pathways in medicine. Other
Biological medicines on the market have also been used to treat
developed diseases by blocking interleukin-1, but none
specifically and exclusively targets interleukin-1 alpha (IL-1a). About it
Additionally, there are no other monoclonal antibody therapies on the market that
is derived unchanged from a natural human immune response.
About XBiotech
XBiotech is a fully integrated global biosciences company dedicated to
entirely of its pioneering role in the discovery, development and commercialization of
therapeutic antibodies based on its proprietary True Human(TM)
committed to technology. XBiotech is currently developing a robust pipeline
of antibody therapies that raise standards of care in oncology and
redefine inflammatory and infectious diseases. Headquartered XBiotech
in Austin, Texas, is also a leader in the development of innovative
biotechnological manufacturing processes, with which urgently needed new ones
Therapies for patients worldwide faster, cheaper and more flexible
can be developed. For more information, see
www.xbiotech.com (http://www.xbiotech.com/).
Contact
Wenyi Wei
[email protected] (mailto:[email protected])
Phone: 512-386-2900
°